Russell Frank Company’s Alexion Pharmaceuticals ALXN Stock Holding History

Russell Frank Company’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$26.1M	Sell	187,099 -109,019	-37%	-$16M	0.05%	476
2015 Q4	$56.7M	Buy	296,118 +3,149	+1%	+$550K	0.1%	235
2015 Q3	$45.8M	Sell	292,969 -8,526	-3%	-$1.56M	0.09%	253
2015 Q2	$54.5M	Buy	301,495 +59,361	+25%	+$10.2M	0.09%	257
2015 Q1	$42M	Buy	242,134 +67,472	+39%	+$12.2M	0.08%	300
2014 Q4	$32.3M	Buy	174,662 +13,896	+9%	+$2.57M	0.06%	380
2014 Q3	$26.7M	Sell	160,766 -30,370	-16%	-$4.99M	0.05%	439
2014 Q2	$31.7M	Buy	191,136 +74,054	+63%	+$11.7M	0.06%	379
2014 Q1	$17.8M	Buy	117,082 +68,597	+141%	+$10.9M	0.03%	599
2013 Q4	$7.7M	Sell	48,485 -44,012	-48%	-$5.28M	0.01%	986
2013 Q3	$10.7M	Sell	92,497 -21,421	-19%	-$2.35M	0.02%	862
2013 Q2	$10.5M	Buy	+113,918	New	+$11M	0.02%	827

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Russell Frank Company's ALXN Position: Q1 2016 in Review

Russell Frank Company reduced its Alexion Pharmaceuticals (ALXN) stake by 37% in Q1 2016, selling an estimated $16M and leaving 187,099 shares worth $26.1M. The position accounts for 0.05% of the portfolio, ranked #476.

Russell Frank Company first reported a position in ALXN in Q2 2013 and has held it in 12 quarters since. The position peaked at $56.7M in Q4 2015. 518 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

Russell Frank Company held 187,099 shares of Alexion Pharmaceuticals worth $26.1M as of Q1 2016.
Russell Frank Company sold 109,019 Alexion Pharmaceuticals shares in Q1 2016, an estimated $16M.
Alexion Pharmaceuticals made up 0.05% of Russell Frank Company's portfolio in Q1 2016, its #476 holding.
Russell Frank Company first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 12 quarters since.
Russell Frank Company's Alexion Pharmaceuticals position peaked at $56.7M in Q4 2015.
518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.